Mitsubishi UFJ Financial Group Inc. Common Stock vs Novartis AG — how do they compare? Mitsubishi UFJ Financial Group Inc. Common Stock trades at $22.27 (market cap $249.48B), while Novartis AG trades at $143.12 (market cap $268.57B). The key difference: Mitsubishi UFJ Financial Group Inc. Common Stock and Novartis AG are close in size by market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Mitsubishi UFJ Financial Group Inc. Common Stock for 0 Days and Novartis AG for 82 Days on average.
| MUFG | NVS | |
|---|---|---|
Market Cap | $249.48B | $268.57B |
Volume | 4,008,160 | 1,532,573 |
Sector | Financials | Health |
52-Week High | $24.13 | $168.62 |
52-Week Low | $14.62 | $121.80 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $28.96T | $309.89B |
Dividend Yield | 2.4% | 3.31% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mitsubishi UFJ Financial Group is a Japanese financial services company providing banking, lending, securities, and asset management services. Its businesses serve individuals, companies, and institutions worldwide.
Read more on MUFG →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →